Drug

Capsaicin

Approved · EMA

ClassVanilloid receptor openerEmerging researchLate-stage development

Also known as (E)-8-Methyl-N-vanillyl-6-nonenamide, Analgesic Balm with Capsaicin, Arth-RX, Arthricare for Women Moisturizing+39 more

(E)-8-Methyl-N-vanillyl-6-nonenamide, Analgesic Balm with Capsaicin, Arth-RX, Arthricare for Women Moisturizing, Arthricare for Women Ultra Strength, Arthritis Formula, Arthur Itis, Atomic Balm, Axsain, Capsaicin Topical, Capsaicin-Menthol, Capsin, Capzasin Quick Relief, Capzasin-HP, Capzasin-HP Arthritis Formula, Capzasin-P, Cartilade, Castiva Warming, Dendracin Neurodendraxcin, Dolorac, Doloracin with Lidocaine, Equi-Block Original, Isodecenoic acid vanillylamide, LidoPro, Medi-Derm, Medi-Derm with Lidocaine, Medrox, Menthac Arthritis Cream with Capsaicin, Qutenza, RT Capsin, Red Hot, Satogesic Hot, Sloan's Liniment, WellPatch, Xoten-C, ZIKS Pain Relief, Zostrix, Zostrix Joint & Arthritis Pain Relief, Zostrix Neuropathy, Zostrix Sports, Zostrix-HP, trans-8-Methyl-N-vanillyl-6-nonenamide, Capsaicina.

RxNorm1992 ChEMBLCHEMBL294199 ATCN01BX04 ATCM02AB01UNIIS07O44R1ZM

Research papers

Active clinical trials

TRPV1

Primary target

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Multicentric, Open, Randomized Study Comparing Topical Treatment by Patch of Capsaicin to 8% (Qutenza) to Pregabalin Oral in the Early Treatment of Neuropathic Pain After Primary Surgery for Breast Cancer

Clinical trial2026-05-05Results posted · ClinicalTrials.gov

Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy : a Phase 3 Randomized Multicentric Open-label Study.

Clinical trial2026-03-31Results expected Q1 2028 · ClinicalTrials.gov

The Pain Biomarker Study: Changes in Circulating Pain Signalling Molecules With Activation of Pain Receptors

Clinical trial2026-02-18Results expected Q2 2028 · ClinicalTrials.gov

A Comparison Between Qutenza and Duloxetine for the Treatment of Painful Chemotherapy-induced Peripheral Neuropathy: a Pragmatic Randomized Controlled Trial

Clinical trial2024-12-31Primary completion · ClinicalTrials.gov

A Randomized, Multi-Dose, Placebo-Controlled Pain Relief Study of 0.25% 920-CGS-200 in Subjects With Preexisting Knee Pain (for at Least 6 Months) Caused by Osteoarthritis (OA)

Clinical trial2024-10-31Results posted · ClinicalTrials.gov

A Functional Magnetic Resonance Imaging Study to Investigate ATP-sensitive Cough Neural Pathways in Patients With Chronic Cough Hypersensitivity

Clinical trial2024-08-22Results posted · ClinicalTrials.gov

The Influence of Topical Capsaicin on Thermoregulatory and Perceptual Outcomes During Exercise Within the Heat

Clinical trial2024-03-15Results posted · ClinicalTrials.gov

Burning Mouth Syndrome - Optimized Diagnostic Criteria and Treatment

Clinical trial2023-12-31Primary completion · ClinicalTrials.gov

A Pilot Study to Evaluate the Use of Laser Speckle Contrast Imaging on Changes in Dermal Blood Flow Induced by Intradermal Capsaicin and Topical AITC in Healthy Participants

Clinical trial2023-12-15Completed · ClinicalTrials.gov

Capsaicin, The Vanilloid Receptor TRPV1 Agonist in Neuroprotection: Mechanisms Involved and Significance.

Research2023-07-26Neurochemical research

Effect of Capsaicin on the Augmentation of Cerebral Perfusion. A Phase II Study.

Clinical trial2023-02-28Completed · ClinicalTrials.gov

Approval: Qutenza (EMA)

Regulatory2009-05-15EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Capsaicin

Aliases & brands

(E)-8-Methyl-N-vanillyl-6-nonenamideAnalgesic Balm with CapsaicinArth-RXArthricare for Women MoisturizingArthricare for Women Ultra StrengthArthritis FormulaArthur ItisAtomic BalmAxsainCapsaicin TopicalCapsaicin-MentholCapsinCapzasin Quick ReliefCapzasin-HPCapzasin-HP Arthritis FormulaCapzasin-PCartiladeCastiva WarmingDendracin NeurodendraxcinDoloracDoloracin with LidocaineEqui-Block OriginalIsodecenoic acid vanillylamideLidoProMedi-DermMedi-Derm with LidocaineMedroxMenthac Arthritis Cream with CapsaicinQutenzaRT CapsinRed HotSatogesic HotSloan's LinimentWellPatchXoten-CZIKS Pain ReliefZostrixZostrix Joint & Arthritis Pain ReliefZostrix NeuropathyZostrix SportsZostrix-HPtrans-8-Methyl-N-vanillyl-6-nonenamideCapsaicina

RxNorm CUI

1992

ChEMBL ID

CHEMBL294199

ATC codes

N01BX04M02AB01

UNII

S07O44R1ZM

Primary mechanism

Vanilloid receptor opener

Regulatory jurisdictions

ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Transient receptor potential cation channel subfamily V member 1

TRPV1 · Q8NER1

OPENERVanilloid receptor opener

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2009-05-15

Latest approval

2009-05-15

Authorities

EMA

Total events

emaEuropean Medicines Agency· 1 event

2009-05-15Approval

Approval: Qutenza (EMA)

Indication: Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.